摘要
应用嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR T)治疗急性和慢性淋巴细胞白血病,在近期已取得了新进展。CAR T细胞是通过将T细胞受体基因和抗CD19抗体基因嵌合,转染至T细胞,在体外扩增以后输注给患者来治疗白血病的新型免疫治疗。经过基因改造后的CAR T细胞的表面具有特异性位点,可以识别淋巴细胞白血病中B细胞表面的CD19抗原。CD19抗原的持续刺激可使CAR T细胞不断增殖与活化,CAR T在患者体内可以增殖1000倍,有效杀伤急性和慢性淋巴细胞白血病细胞。本文就CAR T细胞及其对急性和慢性淋巴细胞白血病的疗效进行综述。
Bioengineered T cellswhich are the genetically manipulated T cells to express chimeric antigen receptor T Cell（ CAR T）against leukemia-associated specific antigenswere applied to treat acute and chronic lymphocytic leukemia with CAR T.CAR T cells combined with cell-surface binding site and anti-CD19 chimeric antigen receptor can treat diseases through T cells transfection.CAR T cells can recognize the CD19 antigen on B cells with specific cell-surface loci.CAR T cells can proliferate by 1000 times and differentiate in vivo by the CD19 antigen stimulationthereforekill the acute and chronic lymphocytic leukemia cells effectively.This article briefly reviews the CAR T cells and the effect of CAR T cells on acute and chronic lymphoblastic leukemia.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2014年第6期1753-1756,共4页
Journal of Experimental Hematology
基金
国家自然科学基金资助项目(81370612)
